PresentationJohn LeonardPresident, CEO & Director Thank you, Brian. I appreciate the opportunity to give you a sense of where we are, Intellia Therapeutics as we begin the new year here. This is our forward-looking statement. It's available on the website. If you want to examine it further. So Intellia has been a leader in the CRISPR medicine space since its outset in 2014. We've been leaders in many respects, but have emphasized work in vivo treatment of genetic diseases. From our outset in 2014, here we s ...